Publications by authors named "Alexandra Zang"
Article Synopsis
- Axi-cel (axi-cel) and tisagenlecleucel (tisa-cel) are advanced T-cell therapies for treating resistant diffuse large B-cell lymphoma (DLBCL), evaluated in major clinical trials (ZUMA-1 and JULIET) and a French registry that examined data from 729 patients.
- Axi-cel showed better overall survival and progression-free survival compared to tisa-cel but was linked to more severe immune-related side effects, while no significant difference was found in serious cytokine release syndrome.
- The cost-effectiveness analysis indicated that axi-cel is more economically favorable, costing €15,520 per quality-adjusted life year compared to tisa-cel.
